Combining dupilumab with allergen immunotherapy shows promise for severe atopic dermatitis

Combining dupilumab, a biologic therapy, with subcutaneous immunotherapy (SCIT) shows promise as an effective and safe treatment for severe, treatment-refractory atopic dermatitis (AD), according to a study.

The combination therapy significantly reduces disease severity, improves immune markers, and has a favorable safety profile, with only mild and temporary side effects observed.

The study included 48 patients with treatment-refractory AD, all of whom had elevated IgE levels to house dust mite allergens and had been treated for at least 18 months.

The results indicated significant improvements in disease severity, as measured by the Eczema Area and Severity Index and favorable changes in serum biomarkers, including reductions in total IgE and specific IgE levels and increases in allergen-specific IgG4. The combination therapy was well-tolerated, with only mild and temporary side effects reported.

Reference
Kim J, Boo J, Jang H, et al. Combined Dupilumab and Allergen-Specific Immunotherapy in Severe Refractory Atopic Dermatitis. Allergy Asthma Immunol Res. 2024;16(6):682-689. doi: 10.4168/aair.2024.16.6.682. PMID: 39622691.